

ENANTA PHARMACEUTICALS INC  
Form SC 13G/A  
October 27, 2017

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**SCHEDULE 13G/A**

(Amendment No. 1)

Under the Securities Exchange Act of 1934

**ENANTA PHARMACEUTICALS, INC.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**29251M106**

(CUSIP Number)

**October 17, 2017**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
  - Rule 13d-1(c)
  - Rule 13d-1(d)
-

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No.: 29251M106

1	Names of Reporting Persons: AbbVie Inc.		
2	Check the Appropriate Box if a Member of a Group (See Instructions)		
	(a)	<input type="radio"/>	
	(b)	<input type="radio"/>	
3	SEC Use Only		
4	Citizenship or Place of Organization: State of Delaware		
	5	Sole Voting Power:	924,662
Number of Shares Beneficially Owned by Each Reporting Person With	6	Shared Voting Power:	0
	7	Sole Dispositive Power:	924,662
	8	Shared Dispositive Power:	0
9	Aggregate Amount Beneficially Owned by Each Reporting Person: 924,662		
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	<input type="radio"/>	
11	Percent of Class Represented by Amount in Row 9: 4.84 (1)		
12	Type of Reporting Person (See Instructions): CO		

---

(1) This percentage is calculated based upon 19,090,383 shares of the Issuer's Common Stock outstanding as of August 1, 2017, as set forth in Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017, filed with the Securities and Exchange Commission on August 9, 2017.

**Item 1(a).** Name of Issuer:  
Enanta Pharmaceuticals, Inc.

**Item 1(b).** Address of Issuer's Principal Executive Offices:  
500 Arsenal Street  
Watertown, Massachusetts 02472

**Item 2(a).** Name of Person Filing:  
AbbVie Inc.

**Item 2(b).** Address of Principal Business Office or, if none, Residence:  
1 North Waukegan Road  
North Chicago, Illinois 60064-6400

**Item 2(c).** Citizenship:  
Not applicable.

**Item 2(d).** Title of Class of Securities:  
Common Stock

**Item 2(e).** CUSIP Number:  
29251M106

**Item 3.** **If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a)	<input type="radio"/>	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	<input type="radio"/>	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	<input type="radio"/>	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	<input type="radio"/>	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
(e)	<input type="radio"/>	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	<input type="radio"/>	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	<input type="radio"/>	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	<input type="radio"/>	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	<input type="radio"/>	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	<input type="radio"/>	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); and Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with
(k)	<input type="radio"/>	§ 240.13d-1(b)(1)(ii)(J), please specify the type of institution:_____.

**Item 4. Ownership.**

Amount beneficially owned:

**Item 4(a)**

924,662 shares

Percent of class:

**Item 4(b)**

4.84 (1)

Number of shares as to which such person has:

**Item 4(c)**

- |       |  |
|-------|--|
| (i)   | Sole power to vote or to direct the vote:                |
|       | 924,662 shares   |
| (ii)  | Shared power to vote or to direct the vote:              |
|       | 0  |
| (iii) | Sole power to dispose or to direct the disposition of:   |
|       | 924,662 shares   |
| (iv)  | Shared power to dispose or to direct the disposition of: |
|       | 0  |

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

All securities reported in this schedule are owned by the Reporting Person.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

---

(1) This percentage is calculated based upon 19,090,383 shares of the Issuer's Common Stock outstanding as of August 1, 2017, as set forth in Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017, filed with the Securities and Exchange Commission on August 9, 2017.

**Item 10. Certifications.**  
Not applicable.

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 27, 2017

**ABBVIE INC.**

By:	/s/ William J. Chase
Name:	William J. Chase
Title:	Executive Vice President, Chief Financial Officer